Диссертация (1097599), страница 26
Текст из файла (страница 26)
J., Jones, D. P., & Kemp, M. L. (2010). A model of redox kineticsimplicates the thiol proteome in cellular hydrogen peroxide responses.Antioxidants&RedoxSignaling,13(6),731–43.http://doi.org/10.1089/ars.2009.2968Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., …Sliwkowski, M. X. (2002). Targeting ligand-activated ErbB2 signaling inhibitsbreast and prostate tumor growth. Cancer Cell, 2(2), 127–37. Retrieved fromhttp://www.ncbi.nlm.nih.gov/pubmed/12204533Alroy, I., & Yarden, Y. (1997). The ErbB signaling network in embryogenesis andoncogenesis: signal diversification through combinatorial ligand-receptorinteractions.FEBSLetters,410(1),83–6.Retrievedfromhttp://www.ncbi.nlm.nih.gov/pubmed/9247128Amit, I., Wides, R., & Yarden, Y. (2007).
Evolvable signaling networks of receptortyrosine kinases: relevance of robustness to malignancy and to cancer therapy.Molecular Systems Biology, 3, 151. http://doi.org/10.1038/msb4100195Austin, C. D., De Mazière, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C.,Sliwkowski, M. X., … Scheller, R.
H. (2004). Endocytosis and sorting of ErbB2and the site of action of cancer therapeutics trastuzumab and geldanamycin.Molecular Biology of the Cell, 15(12), 5268–82. http://doi.org/10.1091/mbc.E0407-0591Banaszynski, L. A., Liu, C. W., & Wandless, T. J. (2005). Characterization of theFKBP.rapamycin.FRB ternary complex.
Journal of the American ChemicalSociety, 127(13), 4715–21. http://doi.org/10.1021/ja043277yBienert, G. P., Schjoerring, J. K., & Jahn, T. P. (2006). Membrane transport ofhydrogen peroxide. Biochimica et Biophysica Acta, 1758(8), 994–1003.176http://doi.org/10.1016/j.bbamem.2006.02.015Birtwistle, M. R., Hatakeyama, M., Yumoto, N., Ogunnaike, B. A., Hoek, J.
B., &Kholodenko, B. N. (2007). Ligand-dependent responses of the ErbB signalingnetwork: experimental and modeling analyses. Molecular Systems Biology, 3, 144.http://doi.org/10.1038/msb4100188Borisov, N., Aksamitiene, E., Kiyatkin, A., Legewie, S., Berkhout, J., Maiwald, T., …Kholodenko, B. N. (2009). Systems-level interactions between insulin-EGFnetworks amplify mitogenic signaling. Molecular Systems Biology, 5, 256.http://doi.org/10.1038/msb.2009.19Bublil, E. M., & Yarden, Y. (2007). The EGF receptor family: spearheading a mergerof signaling and therapeutics.
Current Opinion in Cell Biology, 19(2), 124–34.http://doi.org/10.1016/j.ceb.2007.02.008Chen, W. W., Schoeberl, B., Jasper, P. J., Niepel, M., Nielsen, U. B., Lauffenburger,D. A., & Sorger, P. K. (2009). Input-output behavior of ErbB signaling pathwaysas revealed by a mass action model trained against dynamic data. MolecularSystems Biology, 5, 239. http://doi.org/10.1038/msb.2008.74Chen, Y., Inoyama, D., Kong, A.-N. T., Beamer, L. J., & Hu, L. (2011). Kineticanalyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptidesequence required for Keap1 binding using surface plasmon resonance.
ChemicalBiology & Drug Design, 78(6), 1014–21. http://doi.org/10.1111/j.17470285.2011.01240.xCho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W.,& Leahy, D. J. (2003). Structure of the extracellular region of HER2 alone and incomplexwiththeHerceptinFab.Nature,421(6924),756–60.http://doi.org/10.1038/nature01392Choi, B.-K., Fan, X., Deng, H., Zhang, N., & An, Z.
(2012). ERBB3 (HER3) is a keysensor in the regulation of ERBB-mediated signaling in both low and high ERBB2(HER2)expressingcancercells.CancerMedicine,1(1),28–38.177http://doi.org/10.1002/cam4.10Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008). Rapamycindifferentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression ofmRNA translation. Proceedings of the National Academy of Sciences of the UnitedStates of America, 105(45), 17414–9.
http://doi.org/10.1073/pnas.0809136105Chorley, B. N., Campbell, M. R., Wang, X., Karaca, M., Sambandan, D., Bangura,F., … Bell, D. A. (2012). Identification of novel NRF2-regulated genes by ChIPSeq: influence on retinoid X receptor alpha. Nucleic Acids Research, 40(15),7416–29. http://doi.org/10.1093/nar/gks409Citri, A., & Yarden, Y. (2006). EGF-ERBB signalling: towards the systems level.NatureReviews.MolecularCellBiology,7(7),505–16.http://doi.org/10.1038/nrm1962Cooke, S. L., Ng, C. K. Y., Melnyk, N., Garcia, M. J., Hardcastle, T., Temple, J., …Brenton, J.
D. (2010). Genomic analysis of genetic heterogeneity and evolution inhigh-gradeserousovariancarcinoma.Oncogene,29(35),4905–13.http://doi.org/10.1038/onc.2010.245Cornish-Bowden, A. (2004). Fundamentals of Enzyme Kinetics (3rd Edition). PortlandPressLtd.Retrievedfromhttps://www.portlandpress.com/pp/books/prod_det.cfm?product=9781855781580Cornish-Bowden, A. (2014). Analysis and interpretation of enzyme kinetic data.PerspectivesinScience,1(1–6),121–125.http://doi.org/10.1016/j.pisc.2014.02.010Draper, N. R., & Smith, H. (2014).
Applied Regression Analysis, 3rd Edition.RetrievedApril14,2016,fromhttp://eu.wiley.com/WileyCDA/WileyTitle/productCd-0471170828.htmlEfeyan, A., & Sabatini, D. M. (2010). mTOR and cancer: many loops in one pathway.CurrentOpinioninCellhttp://doi.org/10.1016/j.ceb.2009.10.007Biology,22(2),169–76.178Efron, B., & Tibshirani, R. (1994). An introduction to the bootstrap. Chapman & Hall.Faratian, D., Goltsov, A., Lebedeva, G., Sorokin, A., Moodie, S., Mullen, P., …Harrison, D. J. (2009).
Systems Biology Reveals New Strategies for PersonalizingCancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab.Cancer Research , 69(16), 6713–6720. http://doi.org/10.1158/0008-5472.CAN09-0777Faratian, D., Zweemer, A. J. M., Nagumo, Y., Sims, A. H., Muir, M., Dodds, M., …Langdon, S. P. (2011). Trastuzumab and pertuzumab produce changes inmorphology and estrogen receptor signaling in ovarian cancer xenografts revealingnew treatment strategies.
Clinical Cancer Research : An Official Journal of theAmericanAssociationforCancerResearch,17(13),4451–61.http://doi.org/10.1158/1078-0432.CCR-10-2461Flågeng, M. H., Knappskog, S., Haynes, B. P., Lønning, P. E., & Mellgren, G. (2013).Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant humanbreasttissue.PloSOne,8(8),e74618.http://doi.org/10.1371/journal.pone.0074618Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A.
M., & Sliwkowski,M. X. (2004). Insights into ErbB signaling from the structure of the ErbB2pertuzumabcomplex.CancerCell,5(4),317–28.Retrievedfromhttp://www.ncbi.nlm.nih.gov/pubmed/15093539Fuentes, G., Scaltriti, M., Baselga, J., & Verma, C. S. (2011). Synergy betweentrastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) fromcolocalization: an in silico based mechanism. Breast Cancer Research : BCR,13(3), R54. http://doi.org/10.1186/bcr2888Garrett, J. T., Sutton, C.
R., Kuba, M. G., Cook, R. S., & Arteaga, C. L. (2013). Dualblockade of HER2 in HER2-overexpressing tumor cells does not completelyeliminate HER3 function. Clinical Cancer Research : An Official Journal of theAmericanAssociationforCancerResearch,19(3),610–9.179http://doi.org/10.1158/1078-0432.CCR-12-2024Ghosh, R., Narasanna, A., Wang, S. E., Liu, S., Chakrabarty, A., Balko, J. M., …Arteaga, C. L. (2011). Trastuzumab has preferential activity against breast cancersdrivenbyHER2homodimers.CancerResearch,71(5),1871–82.http://doi.org/10.1158/0008-5472.CAN-10-1872Goltsov, A., Deeni, Y., Khalil, H., Idowu, M., Kyriakidis, S., Goltsov, G., … Bown, J.(2013). Role of Post-translational Regulation of PTEN Activity in Cancer CellAddiction to Heterozygous PTEN Mutations.
In K. Xu (Ed.), PTEN: Structure,Mechanisms-of-Action, Role in Cell Signaling and Regulation (pp. 173–210).NovaSciencePublishers.Retrievedfromhttps://www.novapublishers.com/catalog/product_info.php?products_id=44640Goltsov, A., Faratian, D., Langdon, S. P., Bown, J., Goryanin, I., & Harrison, D. J.(2011). Compensatory effects in the PI3K/PTEN/AKT signaling networkfollowing receptor tyrosine kinase inhibition. Cellular Signalling, 23(2), 407–416.http://doi.org/10.1016/j.cellsig.2010.10.011Goltsov, A., Faratian, D., Langdon, S. P., Mullen, P., Harrison, D. J., & Bown, J.
(2012).Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKTsignalling network after HER2 inhibition. Cellular Signalling, 24(2), 493–504.http://doi.org/10.1016/j.cellsig.2011.09.030Goltsov, A., Khalil, H., Langdon, S., Harrison, D. J., Bown, J., & Deeni, Y. (2015).Systems biology study of the NRF2-KEAP regulatory mechanism of high levelROS haemostasis... - F1000Research. Retrieved August 30, 2015, fromhttp://f1000research.com/posters/1097504Goltsov, A., Lebedeva, G., Humphery-Smith, I., Goltsov, G., Demin, O., & Goryanin,I. (2010). In Silico Screening of Nonsteroidal Anti-Inflammatory Drugs and TheirCombined Action on Prostaglandin H Synthase-1.
Pharmaceuticals, 3(7), 2059–2081. http://doi.org/10.3390/ph3072059Goltsov, A., Maryashkin, A., Swat, M., Kosinsky, Y., Humphery-Smith, I., Demin,180O., … Lebedeva, G. (2009). Kinetic modelling of NSAID action on COX-1: Focuson in vitro/in vivo aspects and drug combinations. European Journal ofPharmaceuticalSciences,36(1),122–136.http://doi.org/10.1016/j.ejps.2008.10.015Goltsov, A., Tashkandi, G., Langdon, S.
P., Harrison, D. J., & Bown, J. L. (2017).Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-targetinhibitors Rapamycin, BEZ235, and LY294002. European Journal ofPharmaceutical Sciences, 97, 170–181. http://doi.org/10.1016/j.ejps.2016.11.008Holbro, T., & Hynes, N. E. (2004). ErbB receptors: directing key signaling networksthroughout life. Annual Review of Pharmacology and Toxicology, 44, 195–217.http://doi.org/10.1146/annurev.pharmtox.44.101802.121440Hu, H.
(2011). HER receptor-mediated dynamic signalling in breast cancer cells.University of Edinburgh, Edinburgh, UK.Hu, H., Goltsov, A., Bown, J. L., Sims, A. H., Langdon, S. P., Harrison, D. J., &Faratian, D. (2013). Feedforward and feedback regulation of the MAPK and PI3Koscillatory circuit in breast cancer.
Cellular Signalling, 25(1), 26–32.http://doi.org/10.1016/j.cellsig.2012.09.014Huang, W., Jiang, D., Wang, X., Wang, K., Sims, C. E., Allbritton, N. L., & Zhang, Q.(2011). Kinetic analysis of PI3K reactions with fluorescent PIP2 derivatives.AnalyticalandBioanalyticalChemistry,401(6),1881–8.http://doi.org/10.1007/s00216-011-5257-zInoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003).
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
